Diego Castanares‐Zapatero, Laurence Kohn, Marie Dauvrin … Koen Van den Heede
Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment.Full disclaimer·
COVID and COVID vaccination can trigger hair loss, primarily telogen effluvium, due to stress and immune system activation. Proper diagnosis and addressing factors like nutrition and stress are crucial for recovery.
The user experienced hair thinning, possibly due to longCOVID and prediabetes, and saw regrowth after dietary changes and using biotin shampoo. They are taking vitamins and noticed significant hair regrowth, especially at the widow's peak.
The user is experiencing sudden hair loss and is considering micro-needling, low-level light therapy, iron supplements, folihair, and Omega 3. They are hesitant to start finasteride, suspecting the hair loss might be due to telogen effluvium from a past COVID-19 infection.
Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.
The conversation is about long-term finasteride use for hair loss, with users discussing periods of improvement and worsening, and considering switching to dutasteride. Other treatments mentioned include minoxidil, red light therapy, microneedling, and scalp massaging.
PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.